Co-Authors
This is a "connection" page, showing publications co-authored by Meletios Dimopoulos and Sentiljana Gumeni.
Connection Strength
1.777
-
Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients. BMC Med. 2021 08 23; 19(1):208.
Score: 0.241
-
The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment. Blood Cancer J. 2021 08 02; 11(8):138.
Score: 0.240
-
Kinetics of Anti-SARS-CoV-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers. Cells. 2021 07 30; 10(8).
Score: 0.240
-
Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine. Clin Exp Med. 2021 Jul 20.
Score: 0.239
-
Comparison of neutralizing antibody responses against SARS-CoV-2 in healthy volunteers who received the BNT162b2 mRNA or the AZD1222 vaccine: Should the second AZD1222 vaccine dose be given earlier? Am J Hematol. 2021 09 01; 96(9):E321-E324.
Score: 0.237
-
Age-dependent and gender-dependent antibody responses against SARS-CoV-2 in health workers and octogenarians after vaccination with the BNT162b2 mRNA vaccine. Am J Hematol. 2021 07 01; 96(7):E257-E259.
Score: 0.235
-
Seroprevalence of Antibodies against SARS-CoV-2 among the Personnel and Students of the National and Kapodistrian University of Athens, Greece: A Preliminary Report. Life (Basel). 2020 Sep 21; 10(9).
Score: 0.226
-
Systemic IL-15, IFN-?, and IP-10/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients. Cell Rep. 2021 08 10; 36(6):109504.
Score: 0.060
-
SARS-CoV-2 Infection Is Asymptomatic in Nearly Half of Adults with Robust Anti-Spike Protein Receptor-Binding Domain Antibody Response. Vaccines (Basel). 2021 Mar 02; 9(3).
Score: 0.058